| scholarly article | Q13442814 |
| P2093 | author name string | T C Theoharides | |
| K Francis | |||
| A Taliou | |||
| I Tsilioni | |||
| P2860 | cites work | Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report | Q22241500 |
| Identification and Evaluation of Children With Autism Spectrum Disorders | Q22241506 | ||
| Epidemiology of Pervasive Developmental Disorders | Q22241669 | ||
| Advances in autism genetics: on the threshold of a new neurobiology | Q22251023 | ||
| Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis | Q24630557 | ||
| Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1 | Q24649505 | ||
| An infection-based model of neurodevelopmental damage | Q24672338 | ||
| Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders | Q27003260 | ||
| The Isolation of a New Hypotensive Peptide, Neurotensin, from Bovine Hypothalami | Q28245181 | ||
| Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells | Q28373264 | ||
| Environmental toxicants and autism spectrum disorders: a systematic review | Q28397071 | ||
| The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer | Q29617123 | ||
| Neuroglial activation and neuroinflammation in the brain of patients with autism | Q29619689 | ||
| Modeling an autism risk factor in mice leads to permanent immune dysregulation | Q30458844 | ||
| IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation | Q30515381 | ||
| A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties | Q31121766 | ||
| Evidence that brain mast cells can modulate neuroinflammatory responses by tumour necrosis factor-alpha production | Q32063476 | ||
| Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. | Q33641785 | ||
| A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. | Q33664194 | ||
| Mast cells enhance T cell activation: Importance of mast cell-derived TNF. | Q33772139 | ||
| Diagnosis and management of autism in childhood | Q34054956 | ||
| Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. | Q50526066 | ||
| Brain cytokines and neuropsychiatric disorders. | Q51935715 | ||
| Cytokines and the brain. | Q53264592 | ||
| Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia | Q54636849 | ||
| The role of IL-17-secreting mast cells in inflammatory joint disease | Q57667231 | ||
| Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers | Q71569046 | ||
| Absorption, metabolism and health effects of dietary flavonoids in man | Q74069002 | ||
| Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function | Q83859246 | ||
| Metabolism of flavonoids in human: a comprehensive review | Q38192699 | ||
| Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis | Q38220636 | ||
| Corticotropin-releasing hormone, microglia and mental disorders. | Q38227359 | ||
| Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders | Q38351309 | ||
| An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders | Q38451268 | ||
| Mast Cells, Mastocytosis, and Related Disorders | Q38543985 | ||
| Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice | Q39671307 | ||
| Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells | Q41139248 | ||
| Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells | Q42756906 | ||
| Toxicity study of ethanolic extract of Chrysanthemum morifolium in rats | Q42932581 | ||
| Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells | Q43261425 | ||
| Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism | Q43274244 | ||
| Luteolin inhibits mast cell-mediated allergic inflammation | Q43763709 | ||
| Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice | Q44493109 | ||
| Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation | Q46295708 | ||
| Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection | Q48169090 | ||
| Autism spectrum disorders and mastocytosis | Q48345348 | ||
| Maternal poly I:C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat. | Q49145819 | ||
| Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health | Q50303226 | ||
| Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders | Q50306538 | ||
| Inflammatory Activity in Autism Spectrum Disorder. | Q50310808 | ||
| Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children | Q50313430 | ||
| Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders | Q34093753 | ||
| Neurotensin is increased in serum of young children with autistic disorder | Q34114124 | ||
| Mast cell activation and autism | Q34156983 | ||
| Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye? | Q34157800 | ||
| 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome | Q34242515 | ||
| Autism and related disorders | Q34275979 | ||
| Is a subtype of autism an allergy of the brain? | Q34345620 | ||
| Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome | Q34348399 | ||
| Structure-activity relationship of flavonoids derived from medicinal plants in preventing methylmercury-induced mitochondrial dysfunction. | Q34356383 | ||
| RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin | Q34377294 | ||
| Cerebrospinal fluid and serum markers of inflammation in autism | Q34448021 | ||
| Evaluation for safety of antioxidant chemopreventive agents | Q34563425 | ||
| Altered T cell responses in children with autism | Q34577189 | ||
| Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells | Q34599430 | ||
| TNF trafficking to human mast cell granules: mature chain-dependent endocytosis | Q34620371 | ||
| Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process | Q34650833 | ||
| How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis | Q34716842 | ||
| Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism | Q34731122 | ||
| Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain | Q35285811 | ||
| The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells | Q35305446 | ||
| Neuro-inflammation, blood-brain barrier, seizures and autism | Q35800334 | ||
| Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis | Q36054405 | ||
| Elevated serum levels of interleukin-17A in children with autism. | Q36136811 | ||
| Verbal ability, social stress, and anxiety in children with autistic disorder | Q36652345 | ||
| Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder | Q36741348 | ||
| Immune transcriptome alterations in the temporal cortex of subjects with autism. | Q37218842 | ||
| Elevated immune response in the brain of autistic patients | Q37405256 | ||
| Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. | Q37537023 | ||
| Immune modulation of learning, memory, neural plasticity and neurogenesis | Q37802555 | ||
| The role of neurotensin in physiologic and pathologic processes | Q37814885 | ||
| Flavonoids and the CNS. | Q37839688 | ||
| Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults | Q37984014 | ||
| Mast cells, glia and neuroinflammation: partners in crime? | Q38137173 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | autism spectrum disorder | Q1436063 |
| autistic child | Q110955678 | ||
| P304 | page(s) | e647 | |
| P577 | publication date | 2015-09-29 | |
| P1433 | published in | Translational Psychiatry | Q15716636 |
| P1476 | title | Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6. | |
| P478 | volume | 5 |
| Q51237369 | A Luteolin-Loaded Electrospun Fibrous Implantable Device for Potential Therapy of Gout Attacks. |
| Q59326892 | A pilot dose finding study of pioglitazone in autistic children |
| Q40694540 | Antiviral activity of luteolin against Japanese encephalitis virus |
| Q26746354 | Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders |
| Q91781828 | Autism Associated With Anti-NMDAR Encephalitis: Glutamate-Related Therapy |
| Q57456677 | Cathepsin B inhibition ameliorates leukocyte-endothelial adhesion in the BTBR mouse model of autism |
| Q90092665 | Combination of Steroid and Flavonoid for the Treatment of Regressive Autism |
| Q90706593 | Do Alarmins Have a Potential Role in Autism Spectrum Disorders Pathogenesis and Progression? |
| Q64259231 | Enhancement of Exercise Performance by 48 Hours, and 15-Day Supplementation with Mangiferin and Luteolin in Men |
| Q39004831 | Feeding the microbiota-gut-brain axis: diet, microbiome, and neuropsychiatry |
| Q48035730 | IKKβ and mutant huntingtin interactions regulate the expression of IL-34: implications for microglial-mediated neurodegeneration in HD. |
| Q90573516 | IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin |
| Q47564469 | Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment? |
| Q89976944 | Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study‡ |
| Q55236619 | Mangifera indica L. Leaf Extract in Combination With Luteolin or Quercetin Enhances VO2peak and Peak Power Output, and Preserves Skeletal Muscle Function During Ischemia-Reperfusion in Humans. |
| Q92177636 | Mast Cells, Stress, Fear and Autism Spectrum Disorder |
| Q60958413 | Modeling Inflammation in Autism Spectrum Disorders Using Stem Cells |
| Q89477428 | Natural Products and Their Therapeutic Effect on Autism Spectrum Disorder |
| Q37417949 | Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism |
| Q54201255 | Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway. |
| Q92447847 | Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? |
| Q91867592 | Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism |
| Q38910432 | Role of dietary phenols in mitigating microglia-mediated neuroinflammation. |
| Q30248903 | The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health |
| Q91588958 | The association between levels of inflammatory markers in autistic children compared to their unaffected siblings and unrelated healthy controls |
| Q92759825 | The path toward using microbial metabolites as therapies |
| Q51765163 | Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. |
| Q50418437 | Wnt/β-catenin signaling stimulates the expression and synaptic clustering of the autism-associated Neuroligin 3 gene |
Search more.